315 related articles for article (PubMed ID: 33915863)
1. Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation.
Castro LS; Lobo GS; Pereira P; Freire MG; Neves MC; Pedro AQ
Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33915863
[TBL] [Abstract][Full Text] [Related]
2. Biopharmaceuticals from microorganisms: from production to purification.
Jozala AF; Geraldes DC; Tundisi LL; Feitosa VA; Breyer CA; Cardoso SL; Mazzola PG; Oliveira-Nascimento L; Rangel-Yagui CO; Magalhães PO; Oliveira MA; Pessoa A
Braz J Microbiol; 2016 Dec; 47 Suppl 1(Suppl 1):51-63. PubMed ID: 27838289
[TBL] [Abstract][Full Text] [Related]
3. The Minderoo-Monaco Commission on Plastics and Human Health.
Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
[TBL] [Abstract][Full Text] [Related]
4. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation.
Hamrang Z; Rattray NJ; Pluen A
Trends Biotechnol; 2013 Aug; 31(8):448-58. PubMed ID: 23769716
[TBL] [Abstract][Full Text] [Related]
5. Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals.
Zeb A; Rana I; Choi HI; Lee CH; Baek SW; Lim CW; Khan N; Arif ST; Sahar NU; Alvi AM; Shah FA; Din FU; Bae ON; Park JS; Kim JK
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33291312
[TBL] [Abstract][Full Text] [Related]
6. Protein crystals for the delivery of biopharmaceuticals.
Basu SK; Govardhan CP; Jung CW; Margolin AL
Expert Opin Biol Ther; 2004 Mar; 4(3):301-17. PubMed ID: 15006725
[TBL] [Abstract][Full Text] [Related]
7. Exploring the potential of machine learning for more efficient development and production of biopharmaceuticals.
Puranik A; Dandekar P; Jain R
Biotechnol Prog; 2022 Nov; 38(6):e3291. PubMed ID: 35918873
[TBL] [Abstract][Full Text] [Related]
8. Ionic-liquid-based approaches to improve biopharmaceuticals downstream processing and formulation.
Almeida C; Pedro AQ; Tavares APM; Neves MC; Freire MG
Front Bioeng Biotechnol; 2023; 11():1037436. PubMed ID: 36824351
[TBL] [Abstract][Full Text] [Related]
9. Mismatched double-stranded RNA: polyI:polyC12U.
Adis Editorial
Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
[TBL] [Abstract][Full Text] [Related]
10. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
[No Abstract] [Full Text] [Related]
11. The biopharmaceutical industry in China: history and future perspectives.
Gao K; Wang J
Front Med; 2012 Jun; 6(2):101-11. PubMed ID: 22544299
[TBL] [Abstract][Full Text] [Related]
12. License Compliance Issues For Biopharmaceuticals: Special Challenges For Negotiations Between Companies And Non-Profit Research Institutions.
Ponzio TA; Feindt H; Ferguson S
LES Nouv; 2011 Sep; 46(3):216-225. PubMed ID: 22162900
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Biopharmaceuticals in China.
Hu X; Ma Q; Zhang S
Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
[TBL] [Abstract][Full Text] [Related]
15. [Interferon. An overview of the state of basic research with special regard to interferon-gamma].
Günther G; Otto B
Arzneimittelforschung; 1993 Feb; 43(2):182-8. PubMed ID: 7681288
[TBL] [Abstract][Full Text] [Related]
16. Generic chromatography-based purification strategies accelerate the development of downstream processes for biopharmaceutical proteins produced in plants.
Buyel JF; Fischer R
Biotechnol J; 2014 Apr; 9(4):566-77. PubMed ID: 24478119
[TBL] [Abstract][Full Text] [Related]
17. Formulations strategies for biopharmaceuticals--ensuring success to market.
Atkinson EM; Klum W
IDrugs; 2001 May; 4(5):557-60. PubMed ID: 16012901
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
19. From cell factories to patients: Stability challenges in biopharmaceuticals manufacturing and administration with mitigation strategies.
Elsayed A; Jaber N; Al-Remawi M; Abu-Salah K
Int J Pharm; 2023 Oct; 645():123360. PubMed ID: 37657507
[TBL] [Abstract][Full Text] [Related]
20. Production of biopharmaceutical proteins by yeast: advances through metabolic engineering.
Nielsen J
Bioengineered; 2013; 4(4):207-11. PubMed ID: 23147168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
